Tina Susan Nova

Insider Reports History

Entity
Individual
Location
C/O Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, CA
Signature
/s/ Kamal Adawi, as attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Tina Susan Nova:

Stock Role Class Num Shares Value Price $ Report Date Ownership
VERACYTE, INC. President, CLIA U.S. Stock Option (right to buy) 103K $2.74M $26.55 Mar 3, 2022 Direct
VERACYTE, INC. President, CLIA U.S. Common Stock 77K $2.04M $26.54 Mar 3, 2022 Direct
Azenta, Inc. Director Common 6.07K $400K $65.93 Feb 12, 2024 Direct
Azenta, Inc. Director Common Stock 3.6K $209K $57.96 Feb 13, 2023 Direct
EXAGEN INC. Director Stock Option(right to buy) 13.5K Jun 10, 2024 Direct
ARENA PHARMACEUTICALS INC Director Common Stock 0 $98.51 Mar 11, 2022 Direct
ARENA PHARMACEUTICALS INC Director Stock Option (right to buy) 0 Mar 11, 2022 Direct

Insider Reports Filed by Tina Susan Nova

Symbol Company Period Transactions Value $ Form Type Date Filed Role
XGN EXAGEN INC. Jun 10, 2024 1 $0 4 Jun 12, 2024 Director
AZTA Azenta, Inc. Feb 12, 2024 1 -$163K 4 Feb 13, 2024 Director
XGN EXAGEN INC. Jun 15, 2023 1 $0 4 Jun 20, 2023 Executive Chairperson, Director
AZTA Azenta, Inc. Feb 13, 2023 1 $0 4 Feb 15, 2023 Director
AZTA Azenta, Inc. Feb 3, 2023 0 $0 3 Feb 7, 2023 Director
XGN EXAGEN INC. Jun 16, 2022 1 $0 4 Jun 21, 2022 Director
ARNA ARENA PHARMACEUTICALS INC Mar 11, 2022 8 $0 4 Mar 11, 2022 Director
VCYT VERACYTE, INC. Mar 3, 2022 2 $0 4 Mar 7, 2022 President, CLIA U.S.
VCYT VERACYTE, INC. Mar 2, 2022 1 -$298K 4 Mar 4, 2022 President, CLIA U.S.
VCYT VERACYTE, INC. Jan 6, 2022 0 $0 3 Jan 13, 2022 President, CLIA U.S.
XGN EXAGEN INC. Jun 17, 2021 1 $0 4 Jun 21, 2021 Director
ARNA ARENA PHARMACEUTICALS INC Jun 11, 2021 2 $0 4 Jun 15, 2021 Director